BCM
LXRX icon

Bridgeway Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bridgeway Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-135,500
Closed -$534K – 1343
2021
Q4 		$534K Sell
135,500
-244,592
-64% -$1.19M 0.01% 965
2021
Q3 		$1.83M Sell
380,092
-20,000
-5% -$82.1K 0.03% 656
2021
Q2 		$1.84M Sell
400,092
-74,500
-16% -$359K 0.03% 653
2021
Q1 		$2.79M Sell
474,592
-353,600
-43% -$2.45M 0.05% 479
2020
Q4 		$2.83M Buy
828,192
+429,800
+108% +$820K 0.06% 387
2020
Q3 		$574K Hold
398,392
– – 0.01% 838
2020
Q2 		$795K Buy
398,392
+104,792
+36% +$205K 0.02% 729
2020
Q1 		$573K Buy
+293,600
New +$874K 0.01% 720

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return